Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $241.50

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned an average rating of “Moderate Buy” from the twenty-two research firms that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $241.50.

Several research analysts have recently issued reports on the stock. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. Citigroup cut their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Hedge Funds Weigh In On IQVIA

Large investors have recently added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. lifted its stake in shares of IQVIA by 7.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 54,164 shares of the medical research company’s stock valued at $12,835,000 after buying an additional 3,872 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in shares of IQVIA by 14.3% in the third quarter. Coldstream Capital Management Inc. now owns 3,477 shares of the medical research company’s stock valued at $815,000 after acquiring an additional 436 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of IQVIA in the third quarter worth about $470,000. Toronto Dominion Bank grew its position in shares of IQVIA by 11.3% during the third quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock worth $14,317,000 after purchasing an additional 6,149 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its stake in IQVIA by 8.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 80 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $145.40 on Friday. The company has a 50 day simple moving average of $182.32 and a two-hundred day simple moving average of $199.38. IQVIA has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a market capitalization of $25.64 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.